Symbotic Inc. (SYM)
NASDAQ: SYM · Real-Time Price · USD
63.21
+6.64 (11.74%)
At close: Aug 5, 2025, 4:00 PM
62.12
-1.09 (-1.72%)
After-hours: Aug 5, 2025, 7:57 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $37.73, which forecasts a -40.31% decrease in the stock price over the next year. The lowest target is $10 and the highest is $60.
Price Target: $37.73 (-40.31%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 5 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 17 | 17 | 17 | 17 | 17 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $35 → $54 | Buy | Maintains | $35 → $54 | -14.57% | Jul 16, 2025 |
| Northland Capital Markets | Northland Capital Markets | Buy Maintains $35 → $56 | Buy | Maintains | $35 → $56 | -11.41% | Jul 8, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $37 → $29 | Strong Buy | Maintains | $37 → $29 | -54.12% | Apr 14, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $25 → $18 | Hold | Maintains | $25 → $18 | -71.52% | Apr 10, 2025 |
| BWS Financial | BWS Financial | Strong Sell Reiterates $10 | Strong Sell | Reiterates | $10 | -84.18% | Apr 2, 2025 |
Financial Forecast
Revenue This Year
2.23B
from 1.79B
Increased by 24.54%
Revenue Next Year
2.93B
from 2.23B
Increased by 31.39%
EPS This Year
0.21
from -0.14
EPS Next Year
0.49
from 0.21
Increased by 132.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.4B | 3.4B | 4.0B |
| Avg | 2.2B | 2.9B | 3.6B |
| Low | 2.1B | 2.3B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 32.3% | 54.0% | 37.9% |
| Avg | 24.5% | 31.4% | 24.4% |
| Low | 16.7% | 1.8% | 8.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.33 | 0.85 | 1.05 | |
| Avg | 0.21 | 0.49 | 0.92 | |
| Low | 0.13 | 0.25 | 0.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | 303.1% | 114.1% | |
| Avg | - | 132.5% | 87.7% | |
| Low | - | 16.1% | 66.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.